Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 21:03 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2RecruitingINTERVENTIONAL

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

ClinicalTrials.gov · NCT06518837 · Registry updated: 2026-01-21

Condition / research focus: Hormone Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer
Sponsor: Rutgers, The State University of New Jersey
Countries with listed sites: United States
Registry dates and results: Start: 2024-10-30. Completion: 2027-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176 (development code name), Mounjaro (brand name in certain regions), Zepbound (brand name in certain regions)

Where the study takes place — 7 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Trinitas Comprehensive Cancer Center
Elizabeth, New Jersey, United States
Site recruitment: Recruiting
RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton
Hamilton, New Jersey, United States
Site recruitment: Not yet recruiting
RWJBarnabas Health - Cooperman Barnabas, Livingston
Livingston, New Jersey, United States
Site recruitment: Recruiting
RWJBarnabas Health - Monmouth Medical Center
Long Branch, New Jersey, United States
Site recruitment: Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey, United States
Site recruitment: Recruiting
RWJBarnabas Health - Newark Beth Israel Medical Center
Newark, New Jersey, United States
Site recruitment: Recruiting
RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset
Somerville, New Jersey, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants

ClinicalTrials.gov · NCT07350512 · Registry updated: 2026-01-20

Condition / research focus: Glucose Metabolism; Glucagon
Sponsor: Nicolai Jacob Wewer Albrechtsen
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-01-20. Completion: 2027-01-20 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

alanine (other)

Where the study takes place — 1 listed sites

Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery

ClinicalTrials.gov · NCT06500143 · Registry updated: 2026-01-16

Condition / research focus: Gastric Retention
Sponsor: Ciusss de L'Est de l'Île de Montréal
Countries with listed sites: Canada
Registry dates and results: Start: 2024-10-09. Completion: 2025-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gastric ultrasound (diagnostic_test)

Where the study takes place — 1 listed sites

CIUSSS de l'Est de l'Ile de Montréal
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of LY3841136 in Japanese Participants With Obesity or Overweight

ClinicalTrials.gov · NCT06297616 · Registry updated: 2026-01-16

Condition / research focus: Obesity; Overweight
Sponsor: Eli Lilly and Company
Countries with listed sites: Japan
Registry dates and results: Start: 2024-04-15. Completion: 2025-11-21 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LY3841136 (drug)
LY3841136-Placebo (drug)
Tirzepatide (drug)
Tirzepatide-Placebo (drug)

Where the study takes place — 3 listed sites

P-One Clinic
Hachiōji, Tokyo, Japan
Site recruitment: Not reported
Sumida Hospital
Sumida-ku, Tokyo, Japan
Site recruitment: Not reported
Hakata Clinic
Fukuoka, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

ClinicalTrials.gov · NCT05579249 · Registry updated: 2026-01-14

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: United States
Registry dates and results: Start: 2023-01-19. Completion: 2024-11-27 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Wegovy
Orlistat (drug) — also listed as: Xenical
Phentermine/Topiramate (drug) — also listed as: Qsymia
Naltrexone/Bupropion (drug) — also listed as: Contrave
Liraglutide (drug) — also listed as: Saxenda

Where the study takes place — 1 listed sites

Nutrition Research Centre
Loma Linda, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableEnrolling by invitationINTERVENTIONAL

To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period

ClinicalTrials.gov · NCT06904846 · Registry updated: 2026-01-14

Condition / research focus: Diabetes Mellitus; Continuous Glucose Monitoring System
Sponsor: Sinocare
Countries with listed sites: Belgium
Registry dates and results: Start: 2025-04-23. Completion: 2026-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

iCan o3 CGM Continuous Glucose Monitoring System (device)

Where the study takes place — 1 listed sites

UZA ANTWERP UZA Dienst Endocrinologie
Antwerp, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

ClinicalTrials.gov · NCT01851694 · Registry updated: 2026-01-14

Condition / research focus: Cystic Fibrosis; Pancreatic Insufficiency
Sponsor: University of Pennsylvania
Countries with listed sites: United States
Registry dates and results: Start: 2013-05. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 (drug)
GIP (drug) — also listed as: Glucose-dependent insulinotrophic polypeptide

Where the study takes place — 1 listed sites

Children's Hospital of Philadelphia and University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

ClinicalTrials.gov · NCT06802081 · Registry updated: 2026-01-13

Condition / research focus: Atrial Fibrillation; Obesity
Sponsor: The Cleveland Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2025-04-08. Completion: 2027-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Zepbound
Placebo (drug) — also listed as: Normal Saline

Where the study takes place — 1 listed sites

Cleveland Clinic
Cleveland, Ohio, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

ClinicalTrials.gov · NCT06648031 · Registry updated: 2026-01-12

Condition / research focus: Type2diabetes
Sponsor: Lexaria Bioscience Corp.
Countries with listed sites: Australia
Registry dates and results: Start: 2024-12-04. Completion: 2025-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Arm 1 - DehydraTECH-CBD alone (drug)
Arm 2 - DehydraTECH-semaglutide alone (drug)
Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide (drug)
Arm 4 - Rybelsus medication (semaglutide) alone (drug)
Arm 5- Tirzepatide (drug)

Where the study takes place — 7 listed sites

Paratus Clinical Pty Ltd, Blacktown Trial Clinic
Blacktown, New South Wales, Australia
Site recruitment: Not reported
Emeritus - Sydney
Botany, New South Wales, Australia
Site recruitment: Not reported
Canopy Clinical Sutherland
Miranda, New South Wales, Australia
Site recruitment: Not reported
Canopy Clinical Wollongong
Wollongong, New South Wales, Australia
Site recruitment: Not reported
Paratus Clinical Brisbane Pty Ltd
Herston, Queensland, Australia
Site recruitment: Not reported
CMAX Clinical Research
Adelaide, South Australia, Australia
Site recruitment: Not reported
Emeritus - Melbourne
Camberwell, Victoria, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Pancreatic Clamp in NAFLD

ClinicalTrials.gov · NCT05724134 · Registry updated: 2026-01-12

Condition / research focus: Insulin Resistance; Prediabetic State; Hyperinsulinemia; Non-Alcoholic Fatty Liver Disease; Obesity
Sponsor: Columbia University
Countries with listed sites: United States
Registry dates and results: Start: 2023-08-29. Completion: 2025-09-24 (may be estimated). No results posted in this registry response.

Products and interventions (10)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin human (drug)
Octreotide Acetate (drug)
Glucagon (drug)
Growth Hormone, Human (drug)
[6,6-2H2] D-glucose (other) — also listed as: D2-glucose, D2G
20% D-glucose (aq) (drug) — also listed as: D20W
BOOST Plus (dietary_supplement)
CORE Bar (dietary_supplement)
Harvard Apparatus PHD ULTRA CP syringe pump (device)
Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer (device)

Where the study takes place — 1 listed sites

Columbia University Irving Medical Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

ClinicalTrials.gov · NCT06283641 · Registry updated: 2026-01-09

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Taiwan
Registry dates and results: Start: 2024-04-08. Completion: 2025-01-13 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Saxenda®

Where the study takes place — 15 listed sites

Changhua Christian Hospital_Metabolic Dept.
Changhua, Taiwan
Site recruitment: Not reported
Ditmanson Medical Foundation Chia-Yi Christian Hospital
Chiayi City, Taiwan
Site recruitment: Not reported
HsinChu MacKay Memorial Hospital
Hsinchu, Taiwan
Site recruitment: Not reported
HsinChu Municipal MacKay Children's Hospital
Hsinchu, Taiwan
Site recruitment: Not reported
Ton-Yen General Hospital
Hsinchu County, Taiwan
Site recruitment: Not reported
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Site recruitment: Not reported
TZ Clinic
Pingtung County, Taiwan
Site recruitment: Not reported
China Medical University Hospital
Taichung, Taiwan
Site recruitment: Not reported
Kuang Tien General Hospital
Taichung, Taiwan
Site recruitment: Not reported
Tungs Taichung MetroHarbor Hospital
Taichung, Taiwan
Site recruitment: Not reported
National Taiwan University Hospital
Taipei, Taiwan
Site recruitment: Not reported
National Taiwan University Hospital_main
Taipei, Taiwan
Site recruitment: Not reported
Genesis Clinic
Taipei, Taiwan
Site recruitment: Not reported
Taipei Medical University Hospital
Taipei, Taiwan
Site recruitment: Not reported
Chang Gung Memorial Hospital, Linkou
Taoyuan, Taiwan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects

ClinicalTrials.gov · NCT07327281 · Registry updated: 2026-01-08

Condition / research focus: Hyperglycemia
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2025-12-18. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TQF3250 placebo (drug)
TQF3250 capsule (drug)

Where the study takes place — 1 listed sites

Drum Tower Hospital Affiliated to Nanjing University School of Medicine
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4Active, not recruitingINTERVENTIONAL

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

ClinicalTrials.gov · NCT07325435 · Registry updated: 2026-01-08

Condition / research focus: Type 2 Diabetes (T2DM)
Sponsor: MaryAnn Banerji
Countries with listed sites: United States
Registry dates and results: Start: 2024-12-21. Completion: 2028-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SGLT-2 inhibitor (drug) — also listed as: empagliflozin (Jardiance®), dapagliflozin (Farxiga®), canagliflozin (Invokana®), bexagliflozin (Brenzavvy®)
GLP1-RA (drug) — also listed as: liraglutide (Victoza), semaglutide (Ozempic), dulaglutide (Trulicity)

Where the study takes place — 1 listed sites

SUNY Downstate Health Sciences University
Brooklyn, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese

ClinicalTrials.gov · NCT07326111 · Registry updated: 2026-01-08

Condition / research focus: Polycystic Ovary Syndrome (PCOS); Obesity & Overweight
Sponsor: University of Bonn
Countries with listed sites: Germany
Registry dates and results: Start: 2025-12-09. Completion: 2029-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide as an adjunct to lifestyle intervention (drug)
Placebo as an adjunct to lifestyle intervention (drug)

Where the study takes place — 2 listed sites

University Hospital BG Bergmannsheil Bochum General internal medicine, endocrinology and diabetology, gastroenterology and hepatology
Bochum, Germany
Site recruitment: Enrolling by invitation
University Hospital Bonn Division of Endocrinology, Diabetes and Metabolism
Bonn, Germany
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Restoration of Hypoglycemia Awareness With Home-based High Intensity Interval Training

ClinicalTrials.gov · NCT04825366 · Registry updated: 2026-01-08

Condition / research focus: Type 1 Diabetes; Hypoglycemia Unawareness
Sponsor: Institut de Recherches Cliniques de Montreal
Countries with listed sites: Canada
Registry dates and results: Start: 2021-08-03. Completion: 2025-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (13)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Continuous glucose monitoring device (device)
Gold method (other)
Clarke questionnaire (other)
Edinburgh Hypoglycemia Symptom Scale (other)
BAPAD questionnaire (other)
Hypoglycemia Fear Survey II (other)
Physical activity questionnaire (other)
Well-being (other)
Treatment satisfaction (other)
Hypoglycemia diary (other)
Piezo RxD (device)
Heart rate monitor (device)
Exercise diary (other)

Where the study takes place — 1 listed sites

Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

ClinicalTrials.gov · NCT07319975 · Registry updated: 2026-01-06

Condition / research focus: Obesity
Sponsor: Istanbul Galata University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2025-12-29. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)
Tirzepatide (drug)
Tirzepatide+Exercise (behavioral)
Semaglutide+Exercise (behavioral)

Where the study takes place — 1 listed sites

Biruni University
Istanbul, Zeytinburnu, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

Brain Activation and Satiety in Children 2

ClinicalTrials.gov · NCT04520490 · Registry updated: 2026-01-05

Condition / research focus: Childhood Obesity
Sponsor: Seattle Children's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2021-01-28. Completion: 2026-02-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Family Based Behavioral Treatment (behavioral)
Exenatide 2 mg [Bydureon] (drug) — also listed as: Bydureon®
Placebo (drug)

Where the study takes place — 1 listed sites

Seattle Children's Hospital
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

ClinicalTrials.gov · NCT06528405 · Registry updated: 2026-01-02

Condition / research focus: Acute Kidney Injury
Sponsor: National Taiwan University Hospital
Countries with listed sites: Taiwan
Registry dates and results: Start: 2024-11-21. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

dapagliflozin (drug)
Other anti-diabetic drug or no anti-diabetic drug (other)
empagliflozin (drug)
canagliflozin (drug)

Where the study takes place — 1 listed sites

National Taiwan University Hospital
Taipei, Taiwan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

ClinicalTrials.gov · NCT04952779 · Registry updated: 2025-12-31

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: South Korea
Registry dates and results: Start: 2021-06-02. Completion: 2024-12-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Xultophy® (insulin degludec/liraglutide) (drug) — also listed as: insulin degludec/liraglutide

Where the study takes place — 32 listed sites

Daejeon Endo Internal Medicine Clinic
Daejeon, Cheongsa-ro, Seo-gu, South Korea
Site recruitment: Not reported
Soon Chun Hyang University Hospital Cheonan
Cheonan, Chungcheongnam-do, South Korea
Site recruitment: Not reported
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Site recruitment: Not reported
The Catholic University of Korea, ST. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea
Site recruitment: Not reported
Jeonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea
Site recruitment: Not reported
Isam Hospital
Busan, South Korea
Site recruitment: Not reported
Inje University Busan Paik Hospital
Busan, South Korea
Site recruitment: Not reported
Kosin University Gospel Hospital
Busan, South Korea
Site recruitment: Not reported
Keimyung University Dongsan Hospital
Daegu, South Korea
Site recruitment: Not reported
Keimyung University Dongsan Medical Center
Daegu, South Korea
Site recruitment: Not reported
Eulji University Hospital_Daejeon
Daejeon, South Korea
Site recruitment: Not reported
Daejeon Endo Internal Medicine Clinic
Daejeon, South Korea
Site recruitment: Not reported
Chungbuk National University Hospital
Daejeon, South Korea
Site recruitment: Not reported
Dongguk University Ilsan Hospital
Goyang, South Korea
Site recruitment: Not reported
Hyewon Medical Foundation Sejong General Hospital
Gyeonggi-do, South Korea
Site recruitment: Not reported
Ajou University Hospital
Gyeonggi-do, South Korea
Site recruitment: Not reported
Dongtan Jeil Women's Hospital
Gyeonggi-do, South Korea
Site recruitment: Not reported
Gyeongsang National University Hospital
Gyeongsangnam-do, South Korea
Site recruitment: Not reported
Inha University Hospital
Incheon, South Korea
Site recruitment: Not reported
Hanil General Hospital
Seoul, South Korea
Site recruitment: Not reported
Nowon Eulji Medical Center, Eulji University
Seoul, South Korea
Site recruitment: Not reported
Sahm Yook Medical Center
Seoul, South Korea
Site recruitment: Not reported
Yonsei Leehyunchul Internal Medicine
Seoul, South Korea
Site recruitment: Not reported
Inje University Seoul Paik Hospital
Seoul, South Korea
Site recruitment: Not reported
Kyung Hee University Hospital at Gangdong
Seoul, South Korea
Site recruitment: Not reported
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, South Korea
Site recruitment: Not reported
The Catholic University of Korea, Yeouido ST. Mary's Hospital
Seoul, South Korea
Site recruitment: Not reported
KangNam Sacred Heart Hospital
Seoul, South Korea
Site recruitment: Not reported
Jae Clinic
Seoul, South Korea
Site recruitment: Not reported
Uijeongbu Eulji university Hospital
Uijeongbu-si, South Korea
Site recruitment: Not reported
Ulsan Hospital
Ulsan, South Korea
Site recruitment: Not reported
Ulsan University Hospital
Ulsan, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

ClinicalTrials.gov · NCT07309094 · Registry updated: 2025-12-30

Condition / research focus: Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2
Sponsor: Cardenal Herrera University
Countries with listed sites: Spain
Registry dates and results: Start: 2023-09-15. Completion: 2028-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug) — also listed as: semaglutide, liraglutide, dulaglutide, exenatide
SGLT2 inhibitor (drug) — also listed as: dapagliflozin, empagliflozin, canagliflozin
Tirzepatide (drug)
Other drugs (drug) — also listed as: ARBs, ACE inhibitors, Metformin, DPP4i, non steroidal mineralocorticoid receptor agonists

Where the study takes place — 1 listed sites

Vithas Valencia Consuelo
Valencia, Valencia, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 21:03 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2RecruitingINTERVENTIONAL

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

ClinicalTrials.gov · NCT06518837 · Registry updated: 2026-01-21

Condition / research focus: Hormone Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer
Sponsor: Rutgers, The State University of New Jersey
Countries with listed sites: United States
Registry dates and results: Start: 2024-10-30. Completion: 2027-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176 (development code name), Mounjaro (brand name in certain regions), Zepbound (brand name in certain regions)

Where the study takes place — 7 listed sites

Trinitas Comprehensive Cancer Center
Elizabeth, New Jersey, United States
Site recruitment: Recruiting
RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton
Hamilton, New Jersey, United States
Site recruitment: Not yet recruiting
RWJBarnabas Health - Cooperman Barnabas, Livingston
Livingston, New Jersey, United States
Site recruitment: Recruiting
RWJBarnabas Health - Monmouth Medical Center
Long Branch, New Jersey, United States
Site recruitment: Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey, United States
Site recruitment: Recruiting
RWJBarnabas Health - Newark Beth Israel Medical Center
Newark, New Jersey, United States
Site recruitment: Recruiting
RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset
Somerville, New Jersey, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants

ClinicalTrials.gov · NCT07350512 · Registry updated: 2026-01-20

Condition / research focus: Glucose Metabolism; Glucagon
Sponsor: Nicolai Jacob Wewer Albrechtsen
Countries with listed sites: Denmark
Registry dates and results: Start: 2026-01-20. Completion: 2027-01-20 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

alanine (other)

Where the study takes place — 1 listed sites

Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery

ClinicalTrials.gov · NCT06500143 · Registry updated: 2026-01-16

Condition / research focus: Gastric Retention
Sponsor: Ciusss de L'Est de l'Île de Montréal
Countries with listed sites: Canada
Registry dates and results: Start: 2024-10-09. Completion: 2025-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gastric ultrasound (diagnostic_test)

Where the study takes place — 1 listed sites

CIUSSS de l'Est de l'Ile de Montréal
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of LY3841136 in Japanese Participants With Obesity or Overweight

ClinicalTrials.gov · NCT06297616 · Registry updated: 2026-01-16

Condition / research focus: Obesity; Overweight
Sponsor: Eli Lilly and Company
Countries with listed sites: Japan
Registry dates and results: Start: 2024-04-15. Completion: 2025-11-21 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LY3841136 (drug)
LY3841136-Placebo (drug)
Tirzepatide (drug)
Tirzepatide-Placebo (drug)

Where the study takes place — 3 listed sites

P-One Clinic
Hachiōji, Tokyo, Japan
Site recruitment: Not reported
Sumida Hospital
Sumida-ku, Tokyo, Japan
Site recruitment: Not reported
Hakata Clinic
Fukuoka, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

ClinicalTrials.gov · NCT05579249 · Registry updated: 2026-01-14

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: United States
Registry dates and results: Start: 2023-01-19. Completion: 2024-11-27 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Wegovy
Orlistat (drug) — also listed as: Xenical
Phentermine/Topiramate (drug) — also listed as: Qsymia
Naltrexone/Bupropion (drug) — also listed as: Contrave
Liraglutide (drug) — also listed as: Saxenda

Where the study takes place — 1 listed sites

Nutrition Research Centre
Loma Linda, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableEnrolling by invitationINTERVENTIONAL

To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period

ClinicalTrials.gov · NCT06904846 · Registry updated: 2026-01-14

Condition / research focus: Diabetes Mellitus; Continuous Glucose Monitoring System
Sponsor: Sinocare
Countries with listed sites: Belgium
Registry dates and results: Start: 2025-04-23. Completion: 2026-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

iCan o3 CGM Continuous Glucose Monitoring System (device)

Where the study takes place — 1 listed sites

UZA ANTWERP UZA Dienst Endocrinologie
Antwerp, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

ClinicalTrials.gov · NCT01851694 · Registry updated: 2026-01-14

Condition / research focus: Cystic Fibrosis; Pancreatic Insufficiency
Sponsor: University of Pennsylvania
Countries with listed sites: United States
Registry dates and results: Start: 2013-05. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 (drug)
GIP (drug) — also listed as: Glucose-dependent insulinotrophic polypeptide

Where the study takes place — 1 listed sites

Children's Hospital of Philadelphia and University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

ClinicalTrials.gov · NCT06802081 · Registry updated: 2026-01-13

Condition / research focus: Atrial Fibrillation; Obesity
Sponsor: The Cleveland Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2025-04-08. Completion: 2027-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Zepbound
Placebo (drug) — also listed as: Normal Saline

Where the study takes place — 1 listed sites

Cleveland Clinic
Cleveland, Ohio, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

ClinicalTrials.gov · NCT06648031 · Registry updated: 2026-01-12

Condition / research focus: Type2diabetes
Sponsor: Lexaria Bioscience Corp.
Countries with listed sites: Australia
Registry dates and results: Start: 2024-12-04. Completion: 2025-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Arm 1 - DehydraTECH-CBD alone (drug)
Arm 2 - DehydraTECH-semaglutide alone (drug)
Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide (drug)
Arm 4 - Rybelsus medication (semaglutide) alone (drug)
Arm 5- Tirzepatide (drug)

Where the study takes place — 7 listed sites

Paratus Clinical Pty Ltd, Blacktown Trial Clinic
Blacktown, New South Wales, Australia
Site recruitment: Not reported
Emeritus - Sydney
Botany, New South Wales, Australia
Site recruitment: Not reported
Canopy Clinical Sutherland
Miranda, New South Wales, Australia
Site recruitment: Not reported
Canopy Clinical Wollongong
Wollongong, New South Wales, Australia
Site recruitment: Not reported
Paratus Clinical Brisbane Pty Ltd
Herston, Queensland, Australia
Site recruitment: Not reported
CMAX Clinical Research
Adelaide, South Australia, Australia
Site recruitment: Not reported
Emeritus - Melbourne
Camberwell, Victoria, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Pancreatic Clamp in NAFLD

ClinicalTrials.gov · NCT05724134 · Registry updated: 2026-01-12

Condition / research focus: Insulin Resistance; Prediabetic State; Hyperinsulinemia; Non-Alcoholic Fatty Liver Disease; Obesity
Sponsor: Columbia University
Countries with listed sites: United States
Registry dates and results: Start: 2023-08-29. Completion: 2025-09-24 (may be estimated). No results posted in this registry response.

Products and interventions (10)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin human (drug)
Octreotide Acetate (drug)
Glucagon (drug)
Growth Hormone, Human (drug)
[6,6-2H2] D-glucose (other) — also listed as: D2-glucose, D2G
20% D-glucose (aq) (drug) — also listed as: D20W
BOOST Plus (dietary_supplement)
CORE Bar (dietary_supplement)
Harvard Apparatus PHD ULTRA CP syringe pump (device)
Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer (device)

Where the study takes place — 1 listed sites

Columbia University Irving Medical Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

ClinicalTrials.gov · NCT06283641 · Registry updated: 2026-01-09

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Taiwan
Registry dates and results: Start: 2024-04-08. Completion: 2025-01-13 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Saxenda®

Where the study takes place — 15 listed sites

Changhua Christian Hospital_Metabolic Dept.
Changhua, Taiwan
Site recruitment: Not reported
Ditmanson Medical Foundation Chia-Yi Christian Hospital
Chiayi City, Taiwan
Site recruitment: Not reported
HsinChu MacKay Memorial Hospital
Hsinchu, Taiwan
Site recruitment: Not reported
HsinChu Municipal MacKay Children's Hospital
Hsinchu, Taiwan
Site recruitment: Not reported
Ton-Yen General Hospital
Hsinchu County, Taiwan
Site recruitment: Not reported
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Site recruitment: Not reported
TZ Clinic
Pingtung County, Taiwan
Site recruitment: Not reported
China Medical University Hospital
Taichung, Taiwan
Site recruitment: Not reported
Kuang Tien General Hospital
Taichung, Taiwan
Site recruitment: Not reported
Tungs Taichung MetroHarbor Hospital
Taichung, Taiwan
Site recruitment: Not reported
National Taiwan University Hospital
Taipei, Taiwan
Site recruitment: Not reported
National Taiwan University Hospital_main
Taipei, Taiwan
Site recruitment: Not reported
Genesis Clinic
Taipei, Taiwan
Site recruitment: Not reported
Taipei Medical University Hospital
Taipei, Taiwan
Site recruitment: Not reported
Chang Gung Memorial Hospital, Linkou
Taoyuan, Taiwan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1RecruitingINTERVENTIONAL

A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects

ClinicalTrials.gov · NCT07327281 · Registry updated: 2026-01-08

Condition / research focus: Hyperglycemia
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2025-12-18. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TQF3250 placebo (drug)
TQF3250 capsule (drug)

Where the study takes place — 1 listed sites

Drum Tower Hospital Affiliated to Nanjing University School of Medicine
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4Active, not recruitingINTERVENTIONAL

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

ClinicalTrials.gov · NCT07325435 · Registry updated: 2026-01-08

Condition / research focus: Type 2 Diabetes (T2DM)
Sponsor: MaryAnn Banerji
Countries with listed sites: United States
Registry dates and results: Start: 2024-12-21. Completion: 2028-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SGLT-2 inhibitor (drug) — also listed as: empagliflozin (Jardiance®), dapagliflozin (Farxiga®), canagliflozin (Invokana®), bexagliflozin (Brenzavvy®)
GLP1-RA (drug) — also listed as: liraglutide (Victoza), semaglutide (Ozempic), dulaglutide (Trulicity)

Where the study takes place — 1 listed sites

SUNY Downstate Health Sciences University
Brooklyn, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese

ClinicalTrials.gov · NCT07326111 · Registry updated: 2026-01-08

Condition / research focus: Polycystic Ovary Syndrome (PCOS); Obesity & Overweight
Sponsor: University of Bonn
Countries with listed sites: Germany
Registry dates and results: Start: 2025-12-09. Completion: 2029-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide as an adjunct to lifestyle intervention (drug)
Placebo as an adjunct to lifestyle intervention (drug)

Where the study takes place — 2 listed sites

University Hospital BG Bergmannsheil Bochum General internal medicine, endocrinology and diabetology, gastroenterology and hepatology
Bochum, Germany
Site recruitment: Enrolling by invitation
University Hospital Bonn Division of Endocrinology, Diabetes and Metabolism
Bonn, Germany
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Restoration of Hypoglycemia Awareness With Home-based High Intensity Interval Training

ClinicalTrials.gov · NCT04825366 · Registry updated: 2026-01-08

Condition / research focus: Type 1 Diabetes; Hypoglycemia Unawareness
Sponsor: Institut de Recherches Cliniques de Montreal
Countries with listed sites: Canada
Registry dates and results: Start: 2021-08-03. Completion: 2025-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (13)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Continuous glucose monitoring device (device)
Gold method (other)
Clarke questionnaire (other)
Edinburgh Hypoglycemia Symptom Scale (other)
BAPAD questionnaire (other)
Hypoglycemia Fear Survey II (other)
Physical activity questionnaire (other)
Well-being (other)
Treatment satisfaction (other)
Hypoglycemia diary (other)
Piezo RxD (device)
Heart rate monitor (device)
Exercise diary (other)

Where the study takes place — 1 listed sites

Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

ClinicalTrials.gov · NCT07319975 · Registry updated: 2026-01-06

Condition / research focus: Obesity
Sponsor: Istanbul Galata University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2025-12-29. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)
Tirzepatide (drug)
Tirzepatide+Exercise (behavioral)
Semaglutide+Exercise (behavioral)

Where the study takes place — 1 listed sites

Biruni University
Istanbul, Zeytinburnu, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

Brain Activation and Satiety in Children 2

ClinicalTrials.gov · NCT04520490 · Registry updated: 2026-01-05

Condition / research focus: Childhood Obesity
Sponsor: Seattle Children's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2021-01-28. Completion: 2026-02-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Family Based Behavioral Treatment (behavioral)
Exenatide 2 mg [Bydureon] (drug) — also listed as: Bydureon®
Placebo (drug)

Where the study takes place — 1 listed sites

Seattle Children's Hospital
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

ClinicalTrials.gov · NCT06528405 · Registry updated: 2026-01-02

Condition / research focus: Acute Kidney Injury
Sponsor: National Taiwan University Hospital
Countries with listed sites: Taiwan
Registry dates and results: Start: 2024-11-21. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

dapagliflozin (drug)
Other anti-diabetic drug or no anti-diabetic drug (other)
empagliflozin (drug)
canagliflozin (drug)

Where the study takes place — 1 listed sites

National Taiwan University Hospital
Taipei, Taiwan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

ClinicalTrials.gov · NCT04952779 · Registry updated: 2025-12-31

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: South Korea
Registry dates and results: Start: 2021-06-02. Completion: 2024-12-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Xultophy® (insulin degludec/liraglutide) (drug) — also listed as: insulin degludec/liraglutide

Where the study takes place — 32 listed sites

Daejeon Endo Internal Medicine Clinic
Daejeon, Cheongsa-ro, Seo-gu, South Korea
Site recruitment: Not reported
Soon Chun Hyang University Hospital Cheonan
Cheonan, Chungcheongnam-do, South Korea
Site recruitment: Not reported
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Site recruitment: Not reported
The Catholic University of Korea, ST. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea
Site recruitment: Not reported
Jeonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea
Site recruitment: Not reported
Isam Hospital
Busan, South Korea
Site recruitment: Not reported
Inje University Busan Paik Hospital
Busan, South Korea
Site recruitment: Not reported
Kosin University Gospel Hospital
Busan, South Korea
Site recruitment: Not reported
Keimyung University Dongsan Hospital
Daegu, South Korea
Site recruitment: Not reported
Keimyung University Dongsan Medical Center
Daegu, South Korea
Site recruitment: Not reported
Eulji University Hospital_Daejeon
Daejeon, South Korea
Site recruitment: Not reported
Daejeon Endo Internal Medicine Clinic
Daejeon, South Korea
Site recruitment: Not reported
Chungbuk National University Hospital
Daejeon, South Korea
Site recruitment: Not reported
Dongguk University Ilsan Hospital
Goyang, South Korea
Site recruitment: Not reported
Hyewon Medical Foundation Sejong General Hospital
Gyeonggi-do, South Korea
Site recruitment: Not reported
Ajou University Hospital
Gyeonggi-do, South Korea
Site recruitment: Not reported
Dongtan Jeil Women's Hospital
Gyeonggi-do, South Korea
Site recruitment: Not reported
Gyeongsang National University Hospital
Gyeongsangnam-do, South Korea
Site recruitment: Not reported
Inha University Hospital
Incheon, South Korea
Site recruitment: Not reported
Hanil General Hospital
Seoul, South Korea
Site recruitment: Not reported
Nowon Eulji Medical Center, Eulji University
Seoul, South Korea
Site recruitment: Not reported
Sahm Yook Medical Center
Seoul, South Korea
Site recruitment: Not reported
Yonsei Leehyunchul Internal Medicine
Seoul, South Korea
Site recruitment: Not reported
Inje University Seoul Paik Hospital
Seoul, South Korea
Site recruitment: Not reported
Kyung Hee University Hospital at Gangdong
Seoul, South Korea
Site recruitment: Not reported
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, South Korea
Site recruitment: Not reported
The Catholic University of Korea, Yeouido ST. Mary's Hospital
Seoul, South Korea
Site recruitment: Not reported
KangNam Sacred Heart Hospital
Seoul, South Korea
Site recruitment: Not reported
Jae Clinic
Seoul, South Korea
Site recruitment: Not reported
Uijeongbu Eulji university Hospital
Uijeongbu-si, South Korea
Site recruitment: Not reported
Ulsan Hospital
Ulsan, South Korea
Site recruitment: Not reported
Ulsan University Hospital
Ulsan, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

ClinicalTrials.gov · NCT07309094 · Registry updated: 2025-12-30

Condition / research focus: Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2
Sponsor: Cardenal Herrera University
Countries with listed sites: Spain
Registry dates and results: Start: 2023-09-15. Completion: 2028-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug) — also listed as: semaglutide, liraglutide, dulaglutide, exenatide
SGLT2 inhibitor (drug) — also listed as: dapagliflozin, empagliflozin, canagliflozin
Tirzepatide (drug)
Other drugs (drug) — also listed as: ARBs, ACE inhibitors, Metformin, DPP4i, non steroidal mineralocorticoid receptor agonists

Where the study takes place — 1 listed sites

Vithas Valencia Consuelo
Valencia, Valencia, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →